Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 25 entries
Sorted by: Best Match Show Resources per page
Fast intra-fractional image-guidance with 6D positioning correction reduces delivery uncertainty for stereotactic radiosurgery and radiotherapy.

Journal of radiosurgery and SBRT

Tarnavski N, Engelholm SA, Af Rosenschold PM.
PMID: 29296422
J Radiosurg SBRT. 2016;4(1):15-20.

The purpose of this study is to analyze intra-fractional positioning uncertainty for stereotactic radiotherapy and radiosurgery of cranial tumors. Specifically, we wish to determine the use of intra-fractional image guided patient positioning verification is necessary during delivery of "frameless"...

Cite
Tarnavski N, Engelholm SA, Af Rosenschold PM. Fast intra-fractional image-guidance with 6D positioning correction reduces delivery uncertainty for stereotactic radiosurgery and radiotherapy. J Radiosurg SBRT. 2016;4(1):15-20
Tarnavski, N., Engelholm, S. A., & Af Rosenschold, P. M. (2016). Fast intra-fractional image-guidance with 6D positioning correction reduces delivery uncertainty for stereotactic radiosurgery and radiotherapy. Journal of radiosurgery and SBRT, 4(1), 15-20.
Tarnavski, Nikolai, et al. "Fast intra-fractional image-guidance with 6D positioning correction reduces delivery uncertainty for stereotactic radiosurgery and radiotherapy." Journal of radiosurgery and SBRT vol. 4,1 (2016): 15-20.
Tarnavski N, Engelholm SA, Af Rosenschold PM. Fast intra-fractional image-guidance with 6D positioning correction reduces delivery uncertainty for stereotactic radiosurgery and radiotherapy. J Radiosurg SBRT. 2016;4(1):15-20. PMID: 29296422; PMCID: PMC5658830.
Copy Download .nbib Format: NLM
Glucocorticoid-induced diabetes in patients with metastatic spinal cord compression.

Endocrine connections

Schultz H, Engelholm SA, Harder E, Pedersen-Bjergaard U, Kristensen PL.
PMID: 29669805
Endocr Connect. 2018 May;7(5):719-726. doi: 10.1530/EC-18-0088. Epub 2018 Apr 18.

BACKGROUND: The risk of developing diabetes mellitus (DM) during treatment with high-dose glucocorticoids is unknown and monitoring of glucose is random in many settings.OBJECTIVE: To determine incidence of and risk factors for induction of DM during high-dose glucocorticoid therapy...

Cite
Schultz H, Engelholm SA, Harder E, et al. Glucocorticoid-induced diabetes in patients with metastatic spinal cord compression. Endocr Connect. 2018;7(5):719-726doi: 10.1530/EC-18-0088.
Schultz, H., Engelholm, S. A., Harder, E., Pedersen-Bjergaard, U., & Kristensen, P. L. (2018). Glucocorticoid-induced diabetes in patients with metastatic spinal cord compression. Endocrine connections, 7(5), 719-726. https://doi.org/10.1530/EC-18-0088
Schultz, Helga, et al. "Glucocorticoid-induced diabetes in patients with metastatic spinal cord compression." Endocrine connections vol. 7,5 (2018): 719-726. doi: https://doi.org/10.1530/EC-18-0088
Schultz H, Engelholm SA, Harder E, Pedersen-Bjergaard U, Kristensen PL. Glucocorticoid-induced diabetes in patients with metastatic spinal cord compression. Endocr Connect. 2018 May;7(5):719-726. doi: 10.1530/EC-18-0088. Epub 2018 Apr 18. PMID: 29669805; PMCID: PMC5952240.
Copy Download .nbib Format: NLM
Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors.

Clinical and translational radiation oncology

Astradsson A, Munck Af Rosenschöld P, Poulsgaard L, Ohlhues L, Engelholm SA, Feldt-Rasmussen U, Marsh R, Roed H, Juhler M.
PMID: 30815592
Clin Transl Radiat Oncol. 2019 Feb 07;15:93-98. doi: 10.1016/j.ctro.2019.02.001. eCollection 2019 Feb.

BACKGROUND: The purpose of this study was to examine the occurrence of cerebral infarction (ischemic stroke), in a large combined cohort of patients with anterior skull base meningiomas, pituitary adenomas and craniopharyngiomas, after fractionated stereotactic radiation therapy (FSRT).MATERIAL AND...

Cite
Astradsson A, Munck Af Rosenschöld P, Poulsgaard L, et al. Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors. Clin Transl Radiat Oncol. 2019;15:93-98doi: 10.1016/j.ctro.2019.02.001.
Astradsson, A., Munck Af Rosenschöld, P., Poulsgaard, L., Ohlhues, L., Engelholm, S. A., Feldt-Rasmussen, U., Marsh, R., Roed, H., & Juhler, M. (2019). Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors. Clinical and translational radiation oncology, 1593-98. https://doi.org/10.1016/j.ctro.2019.02.001
Astradsson, Arnar, et al. "Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors." Clinical and translational radiation oncology vol. 15 (2019): 93-98. doi: https://doi.org/10.1016/j.ctro.2019.02.001
Astradsson A, Munck Af Rosenschöld P, Poulsgaard L, Ohlhues L, Engelholm SA, Feldt-Rasmussen U, Marsh R, Roed H, Juhler M. Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors. Clin Transl Radiat Oncol. 2019 Feb 07;15:93-98. doi: 10.1016/j.ctro.2019.02.001. eCollection 2019 Feb. PMID: 30815592; PMCID: PMC6378839.
Copy Download .nbib Format: NLM
Anal Cancer debuting as Cancer of Unknown Primary.

Rare tumors

Sveistrup J, Loft A, Engelholm SA.
PMID: 21769317
Rare Tumors. 2011 Apr 04;3(2):e18. doi: 10.4081/rt.2011.e18.

Anal cancer usually presents with a visible or palpable tumour. In this case we describe a 54-year old man diagnosed with Cancer of Unknown Primary (CUP) with a single inguinal node as the only finding. Thorough examination failed to...

Cite
Sveistrup J, Loft A, Engelholm SA. Anal Cancer debuting as Cancer of Unknown Primary. Rare Tumors. 2011;3(2):e18doi: 10.4081/rt.2011.e18.
Sveistrup, J., Loft, A., & Engelholm, S. A. (2011). Anal Cancer debuting as Cancer of Unknown Primary. Rare tumors, 3(2), e18. https://doi.org/10.4081/rt.2011.e18
Sveistrup, Joen, et al. "Anal Cancer debuting as Cancer of Unknown Primary." Rare tumors vol. 3,2 (2011): e18. doi: https://doi.org/10.4081/rt.2011.e18
Sveistrup J, Loft A, Engelholm SA. Anal Cancer debuting as Cancer of Unknown Primary. Rare Tumors. 2011 Apr 04;3(2):e18. doi: 10.4081/rt.2011.e18. PMID: 21769317; PMCID: PMC3132122.
Copy Download .nbib Format: NLM
Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society

Eefsen RL, Engelholm L, Alpizar-Alpizar W, Van den Eynden GG, Vermeulen PB, Christensen IJ, Laerum OD, Rolff HC, Høyer-Hansen G, Vainer B, Osterlind K, Illemann M.
PMID: 26268716
Cancer Microenviron. 2015 Aug;8(2):93-100. doi: 10.1007/s12307-015-0172-z. Epub 2015 Aug 14.

Proteolytic activity and inflammation in the tumour microenvironment affects cancer progression. In colorectal cancer (CRC) liver metastases it has been observed that three different immune profiles are present, as well as proteolytic activity, determined by the expression of urokinase-type...

Cite
Eefsen RL, Engelholm L, Alpizar-Alpizar W, et al. Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy. Cancer Microenviron. 2015;8(2):93-100doi: 10.1007/s12307-015-0172-z.
Eefsen, R. L., Engelholm, L., Alpizar-Alpizar, W., Van den Eynden, G. G., Vermeulen, P. B., Christensen, I. J., Laerum, O. D., Rolff, H. C., Høyer-Hansen, G., Vainer, B., Osterlind, K., & Illemann, M. (2015). Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 8(2), 93-100. https://doi.org/10.1007/s12307-015-0172-z
Eefsen, R L, et al. "Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy." Cancer microenvironment : official journal of the International Cancer Microenvironment Society vol. 8,2 (2015): 93-100. doi: https://doi.org/10.1007/s12307-015-0172-z
Eefsen RL, Engelholm L, Alpizar-Alpizar W, Van den Eynden GG, Vermeulen PB, Christensen IJ, Laerum OD, Rolff HC, Høyer-Hansen G, Vainer B, Osterlind K, Illemann M. Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy. Cancer Microenviron. 2015 Aug;8(2):93-100. doi: 10.1007/s12307-015-0172-z. Epub 2015 Aug 14. PMID: 26268716; PMCID: PMC4542827.
Copy Download .nbib Format: NLM
Hilgh Sensitivity and Specificity of PET/CT and Laparoscopic Diagnostic Lymph Node Excision for Lymph Node Metastases in Cervical Cancer Patients.

Practical radiation oncology

Hansen H, Loft A, Berthelsen AK, Lassen S, Høgdall C, Engelholm SA.
PMID: 24674473
Pract Radiat Oncol. 2013 Apr-Jun;3(2):S10. doi: 10.1016/j.prro.2013.01.034. Epub 2013 Mar 25.

No abstract available.

Cite
Hansen H, Loft A, Berthelsen AK, et al. Hilgh Sensitivity and Specificity of PET/CT and Laparoscopic Diagnostic Lymph Node Excision for Lymph Node Metastases in Cervical Cancer Patients. Pract Radiat Oncol. 2013;3(2):S10doi: 10.1016/j.prro.2013.01.034.
Hansen, H., Loft, A., Berthelsen, A. K., Lassen, S., Høgdall, C., & Engelholm, S. A. (2013). Hilgh Sensitivity and Specificity of PET/CT and Laparoscopic Diagnostic Lymph Node Excision for Lymph Node Metastases in Cervical Cancer Patients. Practical radiation oncology, 3(2), S10. https://doi.org/10.1016/j.prro.2013.01.034
Hansen, H, et al. "Hilgh Sensitivity and Specificity of PET/CT and Laparoscopic Diagnostic Lymph Node Excision for Lymph Node Metastases in Cervical Cancer Patients." Practical radiation oncology vol. 3,2 (2013): S10. doi: https://doi.org/10.1016/j.prro.2013.01.034
Hansen H, Loft A, Berthelsen AK, Lassen S, Høgdall C, Engelholm SA. Hilgh Sensitivity and Specificity of PET/CT and Laparoscopic Diagnostic Lymph Node Excision for Lymph Node Metastases in Cervical Cancer Patients. Pract Radiat Oncol. 2013 Apr-Jun;3(2):S10. doi: 10.1016/j.prro.2013.01.034. Epub 2013 Mar 25. PMID: 24674473.
Copy Download .nbib Format: NLM
Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment.

Oncogene

Fjæstad KY, Rømer AMA, Goitea V, Johansen AZ, Thorseth ML, Carretta M, Engelholm LH, Grøntved L, Junker N, Madsen DH.
PMID: 35017664
Oncogene. 2022 Jan 11; doi: 10.1038/s41388-021-02170-0. Epub 2022 Jan 11.

The development of immune checkpoint inhibitors (ICI) marks an important breakthrough of cancer therapies in the past years. However, only a limited fraction of patients benefit from such treatments, prompting the search for immune modulating agents that can improve...

Cite
Fjæstad KY, Rømer AMA, Goitea V, et al. Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment. Oncogene. 2022;doi: 10.1038/s41388-021-02170-0.
Fjæstad, K. Y., Rømer, A. M. A., Goitea, V., Johansen, A. Z., Thorseth, M. L., Carretta, M., Engelholm, L. H., Grøntved, L., Junker, N., & Madsen, D. H. (2022). Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment. Oncogene, . https://doi.org/10.1038/s41388-021-02170-0
Fjæstad, Klaire Yixin, et al. "Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment." Oncogene vol. (2022). doi: https://doi.org/10.1038/s41388-021-02170-0
Fjæstad KY, Rømer AMA, Goitea V, Johansen AZ, Thorseth ML, Carretta M, Engelholm LH, Grøntved L, Junker N, Madsen DH. Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment. Oncogene. 2022 Jan 11; doi: 10.1038/s41388-021-02170-0. Epub 2022 Jan 11. PMID: 35017664.
Copy Download .nbib Format: NLM
Decrease in Pancreatic Perfusion of Patients with Type 2 Diabetes Mellitus Detected by Perfusion Computed Tomography.

Journal of clinical imaging science

Garcia TS, Engelholm JL, Vouche M, Leitão CB.
PMID: 35003832
J Clin Imaging Sci. 2021 Sep 27;11:50. doi: 10.25259/JCIS_72_2021. eCollection 2021.

OBJECTIVES: The objectives of the study was to compare pancreatic perfusion by computed tomography in type 2 diabetes and non-diabetic subjects.MATERIAL AND METHODS: In this case-control study, 17 patients with type 2 diabetes and 22 non-diabetic controls were examined...

Cite
Garcia TS, Engelholm JL, Vouche M, et al. Decrease in Pancreatic Perfusion of Patients with Type 2 Diabetes Mellitus Detected by Perfusion Computed Tomography. J Clin Imaging Sci. 2021;11:50doi: 10.25259/JCIS_72_2021.
Garcia, T. S., Engelholm, J. L., Vouche, M., & Leitão, C. B. (2021). Decrease in Pancreatic Perfusion of Patients with Type 2 Diabetes Mellitus Detected by Perfusion Computed Tomography. Journal of clinical imaging science, 1150. https://doi.org/10.25259/JCIS_72_2021
Garcia, Tiago Severo, et al. "Decrease in Pancreatic Perfusion of Patients with Type 2 Diabetes Mellitus Detected by Perfusion Computed Tomography." Journal of clinical imaging science vol. 11 (2021): 50. doi: https://doi.org/10.25259/JCIS_72_2021
Garcia TS, Engelholm JL, Vouche M, Leitão CB. Decrease in Pancreatic Perfusion of Patients with Type 2 Diabetes Mellitus Detected by Perfusion Computed Tomography. J Clin Imaging Sci. 2021 Sep 27;11:50. doi: 10.25259/JCIS_72_2021. eCollection 2021. PMID: 35003832; PMCID: PMC8730536.
Copy Download .nbib Format: NLM
Target definition in radiotherapy of prostate cancer using magnetic resonance imaging only workflow.

Physics and imaging in radiation oncology

Gunnlaugsson A, Persson E, Gustafsson C, Kjellén E, Ambolt P, Engelholm S, Nilsson P, Olsson LE.
PMID: 33458431
Phys Imaging Radiat Oncol. 2019 Mar 20;9:89-91. doi: 10.1016/j.phro.2019.03.004. eCollection 2019 Jan.

In magnetic resonance (MR) only radiotherapy, the target delineation needs to be performed without computed tomography (CT). We investigated in thirteen patients with prostate cancer, how the clinical target volume (CTV) was affected, when the target delineation procedure was...

Cite
Gunnlaugsson A, Persson E, Gustafsson C, et al. Target definition in radiotherapy of prostate cancer using magnetic resonance imaging only workflow. Phys Imaging Radiat Oncol. 2019;9:89-91doi: 10.1016/j.phro.2019.03.004.
Gunnlaugsson, A., Persson, E., Gustafsson, C., Kjellén, E., Ambolt, P., Engelholm, S., Nilsson, P., & Olsson, L. E. (2019). Target definition in radiotherapy of prostate cancer using magnetic resonance imaging only workflow. Physics and imaging in radiation oncology, 989-91. https://doi.org/10.1016/j.phro.2019.03.004
Gunnlaugsson, Adalsteinn, et al. "Target definition in radiotherapy of prostate cancer using magnetic resonance imaging only workflow." Physics and imaging in radiation oncology vol. 9 (2019): 89-91. doi: https://doi.org/10.1016/j.phro.2019.03.004
Gunnlaugsson A, Persson E, Gustafsson C, Kjellén E, Ambolt P, Engelholm S, Nilsson P, Olsson LE. Target definition in radiotherapy of prostate cancer using magnetic resonance imaging only workflow. Phys Imaging Radiat Oncol. 2019 Mar 20;9:89-91. doi: 10.1016/j.phro.2019.03.004. eCollection 2019 Jan. PMID: 33458431; PMCID: PMC7807603.
Copy Download .nbib Format: NLM
Inhibitory Monoclonal Antibodies against Mouse Proteases Raised in Gene-Deficient Mice Block Proteolytic Functions in vivo.

Frontiers in pharmacology

Lund IK, Rasch MG, Ingvarsen S, Pass J, Madsen DH, Engelholm LH, Behrendt N, Høyer-Hansen G.
PMID: 22754528
Front Pharmacol. 2012 Jun 28;3:122. doi: 10.3389/fphar.2012.00122. eCollection 2012.

Identification of targets for cancer therapy requires the understanding of the in vivo roles of proteins, which can be derived from studies using gene-targeted mice. An alternative strategy is the administration of inhibitory monoclonal antibodies (mAbs), causing acute disruption...

Cite
Lund IK, Rasch MG, Ingvarsen S, et al. Inhibitory Monoclonal Antibodies against Mouse Proteases Raised in Gene-Deficient Mice Block Proteolytic Functions in vivo. Front Pharmacol. 2012;3:122doi: 10.3389/fphar.2012.00122.
Lund, I. K., Rasch, M. G., Ingvarsen, S., Pass, J., Madsen, D. H., Engelholm, L. H., Behrendt, N., & Høyer-Hansen, G. (2012). Inhibitory Monoclonal Antibodies against Mouse Proteases Raised in Gene-Deficient Mice Block Proteolytic Functions in vivo. Frontiers in pharmacology, 3122. https://doi.org/10.3389/fphar.2012.00122
Lund, Ida K, et al. "Inhibitory Monoclonal Antibodies against Mouse Proteases Raised in Gene-Deficient Mice Block Proteolytic Functions in vivo." Frontiers in pharmacology vol. 3 (2012): 122. doi: https://doi.org/10.3389/fphar.2012.00122
Lund IK, Rasch MG, Ingvarsen S, Pass J, Madsen DH, Engelholm LH, Behrendt N, Høyer-Hansen G. Inhibitory Monoclonal Antibodies against Mouse Proteases Raised in Gene-Deficient Mice Block Proteolytic Functions in vivo. Front Pharmacol. 2012 Jun 28;3:122. doi: 10.3389/fphar.2012.00122. eCollection 2012. PMID: 22754528; PMCID: PMC3384954.
Copy Download .nbib Format: NLM
Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring.

Diagnostics (Basel, Switzerland)

Zornhagen KW, Clausen MM, Hansen AE, Law I, McEvoy FJ, Engelholm SA, Kjær A, Kristensen AT.
PMID: 26854160
Diagnostics (Basel). 2015 Sep 11;5(3):372-82. doi: 10.3390/diagnostics5030372.

Glycolysis, hypoxia, and proliferation are important factors in the tumor microenvironment contributing to treatment-resistant aggressiveness. Imaging these factors using combined functional positron emission tomography and computed tomography can potentially guide diagnosis and management of cancer patients. A dog with...

Cite
Zornhagen KW, Clausen MM, Hansen AE, et al. Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring. Diagnostics (Basel). 2015;5(3):372-82doi: 10.3390/diagnostics5030372.
Zornhagen, K. W., Clausen, M. M., Hansen, A. E., Law, I., McEvoy, F. J., Engelholm, S. A., Kjær, A., & Kristensen, A. T. (2015). Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring. Diagnostics (Basel, Switzerland), 5(3), 372-82. https://doi.org/10.3390/diagnostics5030372
Zornhagen, Kamilla Westarp, et al. "Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring." Diagnostics (Basel, Switzerland) vol. 5,3 (2015): 372-82. doi: https://doi.org/10.3390/diagnostics5030372
Zornhagen KW, Clausen MM, Hansen AE, Law I, McEvoy FJ, Engelholm SA, Kjær A, Kristensen AT. Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring. Diagnostics (Basel). 2015 Sep 11;5(3):372-82. doi: 10.3390/diagnostics5030372. PMID: 26854160; PMCID: PMC4665600.
Copy Download .nbib Format: NLM
Stereotactic radiosurgery versus decompressive surgery followed by postoperative radiotherapy for metastatic spinal cord compression (STEREOCORD): Study protocol of a randomized non-inferiority trial.

Journal of radiosurgery and SBRT

Suppli MH, Af Rosenschold PM, Pappot H, Dahl B, Morgen SS, Vogelius IR, Engelholm SA.
PMID: 29296431
J Radiosurg SBRT. 2016;4(1):S1-S9.

Current treatment standard for patients with metastatic spinal cord compression (MSCC) is decompressive surgery followed by radiotherapy. Stereotactic radiosurgery (SRS) could be considered a treatment option for MSCC for patients with minor neurologic deficits. If SRS is safely and...

Cite
Suppli MH, Af Rosenschold PM, Pappot H, et al. Stereotactic radiosurgery versus decompressive surgery followed by postoperative radiotherapy for metastatic spinal cord compression (STEREOCORD): Study protocol of a randomized non-inferiority trial. J Radiosurg SBRT. 2016;4(1):S1-S9
Suppli, M. H., Af Rosenschold, P. M., Pappot, H., Dahl, B., Morgen, S. S., Vogelius, I. R., & Engelholm, S. A. (2016). Stereotactic radiosurgery versus decompressive surgery followed by postoperative radiotherapy for metastatic spinal cord compression (STEREOCORD): Study protocol of a randomized non-inferiority trial. Journal of radiosurgery and SBRT, 4(1), S1-S9.
Suppli, Morten H, et al. "Stereotactic radiosurgery versus decompressive surgery followed by postoperative radiotherapy for metastatic spinal cord compression (STEREOCORD): Study protocol of a randomized non-inferiority trial." Journal of radiosurgery and SBRT vol. 4,1 (2016): S1-S9.
Suppli MH, Af Rosenschold PM, Pappot H, Dahl B, Morgen SS, Vogelius IR, Engelholm SA. Stereotactic radiosurgery versus decompressive surgery followed by postoperative radiotherapy for metastatic spinal cord compression (STEREOCORD): Study protocol of a randomized non-inferiority trial. J Radiosurg SBRT. 2016;4(1):S1-S9. PMID: 29296431; PMCID: PMC5658847.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 25 entries